Company: OSRH
Filing Date: 2025-11-25
Form Type: 8-K
Source: 0001213900-25-114496
Chunk: 1

Company: OSR Holdings, Inc.
Filing Date: 2025-11-25
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01. Other Events

On November 21, 2025, Vaximm AG, a Swiss-based subsidiary of OSR Holdings,
Inc., entered into a non-binding Global License Agreement Term Sheet with BCM Europe AG (“ BCME”), the largest shareholder
of the Company.

The Term Sheet outlines the principal terms under which Vaximm and
BCME intend to negotiate a definitive global license agreement relating to the Company’s VXM01 oral cancer immunotherapy platform.
The Term Sheet includes an exclusivity period for negotiations and certain binding provisions, but does not constitute a definitive agreement
and does not impose material obligations on the Company at this stage.

A copy of the Term Sheet is filed as Exhibit 10.1 to this Current Report
on Form 8-K.

Item 9.01. Financial Statements and Exhibits